Search
Hengrui Medicine (600276.SH): Amapicitin Sulfate Tablets Secure New Drug Registration Approval
1 week ago /
Read about 0 minute
Author：小编
Hengrui Medicine's proprietary class 1 innovative drug, Amapicitin Sulfate Tablets, has garnered approval from the National Medical Products Administration for a novel indication: the treatment of severe alopecia areata in adults. This potent medication, known as a highly selective JAK1 inhibitor, has previously been authorized in China for managing active ankylosing spondylitis, moderate to severe active rheumatoid arthritis, and moderate to severe atopic dermatitis.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
